Media

Publications

The role of DMPK science in improving pharmaceutical research and development efficiency

Kit-Kay Mak*, Ola Epemolu , Mallikarjuna Rao Pichika Drug Discovery Today, https://doi.org/10.1016/j.drudis.2021.11.005  Abstract The successful regulatory authority approval rate of..

Read More

DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis

Charles E. Mowbray*, Stéphanie Braillard, Paul A. Glossop, Gavin A. Whitlock, Robert T. Jacobs, Jason Speake, Bharathi Pandi, Bakela Nare,..

Read More

Live-imaging rate-of-kill compound profiling for Chagas disease drug discovery with a new automated high-content assay

Nina Svensen, Susan Wyllie, David W. Gray, Manu De Rycker PLOS Neglected Tropical Diseases 15(10): e0009870. https://doi.org/10.1371/journal.pntd.0009870 Abstract Chagas disease, caused..

Read More

Genome-scale RNAi screens in African trypanosomes

David Horn Trends in Parasitology 2021. Sep 24;S1471-4922(21)00226-9. doi: 10.1016/j.pt.2021.09.002 Genome-scale genetic screens allow researchers to rapidly identify the genes and..

Read More
View All Publications

Vacancies

Junior In Vitro DMPK Scientist

Job Reference: SLSC1013

Salary: Grade 6,  £27,116 – £33,309

Closing Date: Friday, January 28, 2022

The Drug Discovery Unit (DDU) is a fully integrated drug discovery operation based within a world-class Life Sciences research environment. Our remit is to complement BioPharma activities by tackling both neglected disease drug discovery (leishmaniasis, Chagas disease, TB, Cryptosporidiosis and malaria) and validating novel drug targets across a range of therapeutics areas. The DDU works to Biotech style philosophy and standards incorporating, dynamic, goal driven project management based on Target Product Profiles and Compound Selection Criteria. The…

Read More